Umang Vohra – Global CEO & Managing Director, Cipla
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
It was founded by Khwaja Abdul Hamied as ‘The Chemical, Industrial & Pharmaceutical Laboratories’ in 1935 in Mumbai. The name of the Company was changed to ‘Cipla Limited’ on 20 July 1984. In the year 1985, US FDA approved the company’s bulk drug manufacturing facilities. Led by the founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world. In 1995, Cipla launched Deferiprone, the world’s first oral iron chelator. In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient).
In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited. At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa’s third-biggest pharmaceutical company. The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company, and in 2008 it changed its name to Cipla-Medpro.
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company…
The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how…
“From illness to wellness” – this is what Apollo Life is all about. Ariz Rizvi, president of Apollo Life, gives his insight into the current state of occupational and rehabilitative…
Sridhar Ranganathan, managing director of Allergan, explains how the affiliate revolutionized the ophthalmologic market in India and how it engages with the different stakeholders, ranging from government institutions to the…
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous…
A strong advocate for women’s health and the first managing director of Roche Diagnostics India to be under 40 years old, Dr. Shravan Subramanyam shares his insights on the Indian…
With his over 25 years’ experience in running growing businesses and establishing start-ups, Ranjit Madan, CEO of the Life Sciences Sector Skill Development Council (LSSSDC), explains the journey of the…
Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review Committee on Access to Medicine (ATM), discusses the association’s commitment to assisting the Indian…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence…
As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out…
Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular…
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is…
Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges…
See our Cookie Privacy Policy Here
